JP2022524958A5 - - Google Patents

Info

Publication number
JP2022524958A5
JP2022524958A5 JP2021550221A JP2021550221A JP2022524958A5 JP 2022524958 A5 JP2022524958 A5 JP 2022524958A5 JP 2021550221 A JP2021550221 A JP 2021550221A JP 2021550221 A JP2021550221 A JP 2021550221A JP 2022524958 A5 JP2022524958 A5 JP 2022524958A5
Authority
JP
Japan
Prior art keywords
cells
tcr
antibody
immune cells
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021550221A
Other languages
English (en)
Japanese (ja)
Other versions
JP7638881B2 (ja
JP2022524958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024059 external-priority patent/WO2020191378A1/en
Publication of JP2022524958A publication Critical patent/JP2022524958A/ja
Publication of JP2022524958A5 publication Critical patent/JP2022524958A5/ja
Application granted granted Critical
Publication of JP7638881B2 publication Critical patent/JP7638881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021550221A 2019-03-21 2020-03-20 TCRαβ+細胞の枯渇効率を向上させる方法 Active JP7638881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821768P 2019-03-21 2019-03-21
US62/821,768 2019-03-21
PCT/US2020/024059 WO2020191378A1 (en) 2019-03-21 2020-03-20 METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY

Publications (3)

Publication Number Publication Date
JP2022524958A JP2022524958A (ja) 2022-05-11
JP2022524958A5 true JP2022524958A5 (cg-RX-API-DMAC7.html) 2023-03-24
JP7638881B2 JP7638881B2 (ja) 2025-03-04

Family

ID=70296049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550221A Active JP7638881B2 (ja) 2019-03-21 2020-03-20 TCRαβ+細胞の枯渇効率を向上させる方法

Country Status (12)

Country Link
US (2) US20200317780A1 (cg-RX-API-DMAC7.html)
EP (1) EP3941488B1 (cg-RX-API-DMAC7.html)
JP (1) JP7638881B2 (cg-RX-API-DMAC7.html)
KR (1) KR102942960B1 (cg-RX-API-DMAC7.html)
CN (1) CN113490502A (cg-RX-API-DMAC7.html)
AU (1) AU2020240339B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021018684A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130701A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036043T3 (cg-RX-API-DMAC7.html)
IL (1) IL286909B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010998A (cg-RX-API-DMAC7.html)
WO (1) WO2020191378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184124A1 (en) * 2020-12-14 2022-06-16 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
EP4353253A1 (en) * 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN101072880A (zh) * 2004-07-01 2007-11-14 VIRxSYS股份有限公司 载体包装细胞系
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN107828730B (zh) * 2017-11-07 2019-04-30 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
Withers et al. Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program
Salem et al. Mesenchymal stromal cells: current understanding and clinical status
Aqmasheh et al. Effects of mesenchymal stem cell derivatives on hematopoiesis and hematopoietic stem cells
Pira et al. Selective depletion of αβ T cells and B cells for human leukocyte antigen–haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency
EP3927370B1 (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof
EP3219790B1 (en) Myocardial cell sheet
JP2016509840A5 (cg-RX-API-DMAC7.html)
JP2012521215A5 (cg-RX-API-DMAC7.html)
JP2017524031A (ja) ガンマデルタt細胞およびその使用
TWI410495B (zh) 新穎之人類t細胞群
Fang et al. Technical advances in NK cell-based cellular immunotherapy
Fang et al. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
CN107002036A (zh) 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法
CN102027104A (zh) 含有细胞因子诱导杀伤细胞的细胞群的制造方法
US20260132201A1 (en) METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY
CN119698465A (zh) 快速t细胞制造
O’Neal et al. Traversing the bench to bedside journey for iNKT cell therapies
CN114040967A (zh) 造血干细胞移植后恢复及促进恢复的改进
Stevanović et al. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia
Takahashi et al. T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
JP2024538258A5 (cg-RX-API-DMAC7.html)
US20040147021A1 (en) CD4+CD25 T cells and Tr1-like regulatory T cells
Lee et al. A strategy for enhancing the engraftment of human hematopoietic stem cells in NOD/SCID mice
JP2019508056A5 (cg-RX-API-DMAC7.html)
Schuler et al. Production and properties of large numbers of dendritic cells from human blood